We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
QURE Submits Application for Gene Therapy for Huntington's Disease
Read MoreHide Full Article
Key Takeaways
QURE submitted a BLA for AMT-130 and requested Priority Review from the FDA.
The filings are backed by three-year phase I/II data and an external control group from Enroll-HD.
QURE plans to report four-year study data before quarter-end for added insight into AMT-130.
uniQure N.V. (QURE - Free Report) announced that it has submitted a Biologics License Application (“BLA”) to the FDA seeking accelerated approval for ifezuntirgene inilparvovec (AMT-130), an investigational gene therapy for the treatment of Huntington’s disease.
The company has also requested Priority Review for the BLA. If granted, the designation would reduce the FDA’s review timeline to six months following the agency’s standard 60-day filing review period, potentially accelerating the regulatory path for AMT-130.
In parallel, uniQure submitted a Marketing Authorization Application (“MAA”) for AMT-130 to the United Kingdom’s Medicines and Healthcare products Regulatory Agency, marking another important regulatory milestone for the therapy.
The stock initially gained on the news, but the same was pared by the end of the day. Shares were down 3.41% yesterday.
Year to date, QURE stock surged 93.2% compared with the industry’s growth of 9.7%.
Image Source: Zacks Investment Research
More on QURE’s AMT-130
The BLA and MAA are supported by previously announced three-year data from the phase I/II clinical study of ifezuntirgene inilparvovec, which were compared with a propensity score-matched external control group derived from the Enroll-HD natural history database.
uniQure is conducting two multi-center phase I/II clinical studies evaluating the safety, tolerability and efficacy of ifezuntirgene inilparvovec for the treatment of Huntington’s disease.
The company plans to present four-year data from the ongoing phase I/II clinical studies before the end of the current quarter, providing additional insight into the therapy’s durability and potential clinical benefit.
Ifezuntirgene inilparvovec is the first investigational Huntington’s disease therapy to receive both Breakthrough Therapy and Regenerative Medicine Advanced Therapy designations from the FDA.
The investigational gene therapy has also received Fast Track designation from the regulatory body, underscoring its potential to address an important unmet medical need in Huntington’s disease.
QURE utilizes a proprietary, gene-silencing miQURE platform and incorporates a miRNA, specifically designed to silence the huntingtin gene and the potentially highly toxic exon 1 protein fragment.
QURE’s Regulatory Submission Marks a Key Step Forward
The latest update relieves anxious investors as QURE had earlier suffered a regulatory setback. Shares crashed in March 2026 when the company announced that it had received final meeting minutes from the FDA regarding a type A meeting held in January 2026 to discuss AMT-130.
This meeting was held following an October 2025 pre-BLA meeting.
After receiving the final meeting minutes, the company disclosed that the FDA did not agree that data from the phase I/II studies, when compared with an external control group, were sufficient to serve as the primary evidence of effectiveness needed to support a marketing application for AMT-130.
The FDA then recommended that uniQure conduct a prospective, randomized, double-blind, sham surgery-controlled study.
A potential approval of this gene therapy will be a significant boost for QURE.
Huntington’s disease is a rare, inherited neurodegenerative disorder characterized by progressive motor symptoms, including chorea, as well as behavioral changes and cognitive decline, ultimately leading to worsening physical and mental function.
Over the past 60 days, estimates for Repligen’s 2026 earnings per share have risen from $1.99 to $2.06, while those for 2027 have increased from $2.57 to $2.61 during the same period. RGEN’s shares have gained 5.6% year to date.
Repligen’s earnings beat estimates in each of the trailing four quarters, with the average surprise being 16.80%.
Over the past 60 days, estimates for Anika Therapeutics’ 2026 EPS have risen from 41 cents to $1.05, while those for 2027 have increased from 46 cents to 95 cents over the same period. ANIK’s shares have surged 124.2% year to date.
View the Zacks #1 Rank List
Image: Bigstock
QURE Submits Application for Gene Therapy for Huntington's Disease
Key Takeaways
uniQure N.V. (QURE - Free Report) announced that it has submitted a Biologics License Application (“BLA”) to the FDA seeking accelerated approval for ifezuntirgene inilparvovec (AMT-130), an investigational gene therapy for the treatment of Huntington’s disease.
The company has also requested Priority Review for the BLA. If granted, the designation would reduce the FDA’s review timeline to six months following the agency’s standard 60-day filing review period, potentially accelerating the regulatory path for AMT-130.
In parallel, uniQure submitted a Marketing Authorization Application (“MAA”) for AMT-130 to the United Kingdom’s Medicines and Healthcare products Regulatory Agency, marking another important regulatory milestone for the therapy.
The stock initially gained on the news, but the same was pared by the end of the day. Shares were down 3.41% yesterday.
Year to date, QURE stock surged 93.2% compared with the industry’s growth of 9.7%.
Image Source: Zacks Investment Research
More on QURE’s AMT-130
The BLA and MAA are supported by previously announced three-year data from the phase I/II clinical study of ifezuntirgene inilparvovec, which were compared with a propensity score-matched external control group derived from the Enroll-HD natural history database.
uniQure is conducting two multi-center phase I/II clinical studies evaluating the safety, tolerability and efficacy of ifezuntirgene inilparvovec for the treatment of Huntington’s disease.
The company plans to present four-year data from the ongoing phase I/II clinical studies before the end of the current quarter, providing additional insight into the therapy’s durability and potential clinical benefit.
Ifezuntirgene inilparvovec is the first investigational Huntington’s disease therapy to receive both Breakthrough Therapy and Regenerative Medicine Advanced Therapy designations from the FDA.
The investigational gene therapy has also received Fast Track designation from the regulatory body, underscoring its potential to address an important unmet medical need in Huntington’s disease.
QURE utilizes a proprietary, gene-silencing miQURE platform and incorporates a miRNA, specifically designed to silence the huntingtin gene and the potentially highly toxic exon 1 protein fragment.
uniQure N.V. Price, Consensus and EPS Surprise
uniQure N.V. price-consensus-eps-surprise-chart | uniQure N.V. Quote
QURE’s Regulatory Submission Marks a Key Step Forward
The latest update relieves anxious investors as QURE had earlier suffered a regulatory setback. Shares crashed in March 2026 when the company announced that it had received final meeting minutes from the FDA regarding a type A meeting held in January 2026 to discuss AMT-130.
This meeting was held following an October 2025 pre-BLA meeting.
After receiving the final meeting minutes, the company disclosed that the FDA did not agree that data from the phase I/II studies, when compared with an external control group, were sufficient to serve as the primary evidence of effectiveness needed to support a marketing application for AMT-130.
The FDA then recommended that uniQure conduct a prospective, randomized, double-blind, sham surgery-controlled study.
A potential approval of this gene therapy will be a significant boost for QURE.
Huntington’s disease is a rare, inherited neurodegenerative disorder characterized by progressive motor symptoms, including chorea, as well as behavioral changes and cognitive decline, ultimately leading to worsening physical and mental function.
QURE's Zacks Rank & Stocks to Consider
uniQure currently carries a Zacks Rank #3 (Hold). A couple of better-ranked stocks in the drug/biotech sector are Repligen (RGEN - Free Report) and Anika Therapeutics (ANIK - Free Report) , both sporting a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Over the past 60 days, estimates for Repligen’s 2026 earnings per share have risen from $1.99 to $2.06, while those for 2027 have increased from $2.57 to $2.61 during the same period. RGEN’s shares have gained 5.6% year to date.
Repligen’s earnings beat estimates in each of the trailing four quarters, with the average surprise being 16.80%.
Over the past 60 days, estimates for Anika Therapeutics’ 2026 EPS have risen from 41 cents to $1.05, while those for 2027 have increased from 46 cents to 95 cents over the same period. ANIK’s shares have surged 124.2% year to date.